



QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Listed Entity : ASTRAZENECA PHARMA INDIA LIMITED
 Quarter ending : December 31, 2016

ANNEXURE 1

I. Composition of Board Directors								
Title (Mr./Ms.)	Name of the Director	DIN	Category (Chairperson/Executive/Non- Executive/ Independent/Nominee)	Date of Appointment in the current term/cessation	Tenure*	No. of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	No. of Memberships in Audit/Stakeholder Committee(s) including this listed entity(Refer Regulation 26(1) of Listing Regulations)	No. of Post of Chairperson in Audit/Stakeholder Committee held in listed entities including this listed entity(Refer Regulation 26(1) of Listing Regulations)
Mr.	NARAYAN KEELVEEDHI SESHADRI	00053563	Non-Executive/Independent	30/09/2014	5 years	6	7	3
Ms.	REVATHY ASHOK	00057539	Non-Executive/Independent	02/12/2016		3	7	2
Mr.	SANJAY PRABHAKAR MURDESHWAR	01481811	Executive	02/05/2016	3 years	1	1	0
Mr.	IAN MARTIN DAVID BRIMICOMBE	00764601	Non-Executive	08/09/2006		1	0	0
Mr.	GREGORY DAVID EMIL MUELLER	07667074	Non-Executive	02/12/2016		1	1	0
Mr.	RAJESH MARWAHA	01458768	Executive	02/12/2016	3 years	1	0	0



II. Composition of Committees		
<i>Name of Committee</i>	<i>Name of Committee members</i>	<i>Category (Chairperson/Executive/Non-Executive/Independent/Nominee)</i>
Audit Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
Nomination and Remuneration Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. IAN MARTIN DAVID BRIMICOMBE	Non-Executive
	4. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
Stakeholders' Relationship Committee *	1. Mr. SANJAY MURUDESHWAR	Executive

*The Stakeholders' Relationship Committee consisted of Mr. K.S.Shah and Mr. Sanjay Murdeshwar. However, Mr. K.S.Shah resigned from the Board with effect from December 2, 2016 and consequently cease to be a member of the said committee. Board will induct a member in the place of Mr. K.S.Shah in the ensuing board meeting.

III. Meeting of Board of Directors		
<i>Date(s) of Meeting (If any) in the previous quarter</i>	<i>Date(s) of Meeting (if any) in the relevant quarter</i>	<i>Maximum gap between any two consecutive (in number of days)</i>
9 August 2016	11 November 2016	93 days
	2 December 2016	



IV. Meeting of Committees			
<i>Date(s) of meeting of the Committee in the relevant quarter</i>	<i>Whether requirement of Quorum met (details)</i>	<i>Date (s) of meeting of the committee in the previous quarter</i>	<i>Maximum gap between any two consecutive meetings in number of days*</i>
Audit Committee			
10 November 2016	Yes	9 August 2016	93 days
Nomination & Remuneration Committee			
2 December 2016	Yes	-	300 days

V. Related Party Transactions	
<i>Subject</i>	<i>Compliance status (Yes / No / NA) refer note below</i>
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit committee	Yes



Details of material transactions with Related Party for the quarter ended
December 31, 2016

Name of the Related Party: ***AstraZeneca UK Limited***

<i>Type of Transaction</i>	<i>Amount (INR)</i>
Imports	280,794,601
Reimbursement of Expenses	1,647,680
Total	282,442,281



Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
2. The Composition of the following committees is in terms of SEBI (listing Obligations and Disclosure requirements) Regulations, 2015
 - a) Audit Committee
 - b) Nomination & Remuneration Committee
 - c) Stakeholders Relationship Committee
3. The Committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements Regulations, 2015
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
5. This report and /or the report submitted in the previous quarter has been placed before Board of Directors.

Any comments/observations/advice of Board of Directors may be mentioned here:
NIL

For AstraZeneca Pharma India Limited



Rajesh Marwaha
Chief Financial Officer & Director